The Portfolio That Manages You
Most companies that believe they manage an innovation portfolio are actually managed by one. They have existing product lines that generate the revenue used to fund next-generation development. Those existing lines have customers, commitments, and internal advocates who are very good at making the case for incremental improvement. New growth opportunities have hypothetical future value and internal advocates who are newer, less senior, and less skilled at organizational politics.
The result, almost universally, is a portfolio that concentrates investment in sustaining innovation — improvements to existing products on established performance dimensions — and starves exploratory innovation. The ratio is typically 80-90% sustaining, 10-20% exploratory. Studies of successful industrial innovators suggest the optimal allocation is closer to 70-15-15: 70% core optimization, 15% adjacent innovation, 15% transformational bets.
The gap between where most companies are and where successful innovators allocate is not a resource problem. It is a governance problem. The sustaining innovation pipeline has mechanisms: product roadmaps, customer commitments, engineering schedules, stage-gate reviews. The exploratory pipeline often has nothing but a slide in the annual strategy deck and an “innovation budget” that gets raided when the core business hits a tough quarter.
Innovation portfolio management, done properly, is the set of structures and processes that prevent this from happening — that ensure resources flow to the full range of innovation types in proportions that match the strategic intent, not just the organizational gravity.
The Three Horizons Are Still Useful — If You Use Them Right
The McKinsey Three Horizons framework — Horizon 1 (core), Horizon 2 (adjacent), Horizon 3 (transformational) — has become so widely referenced that it has lost much of its practical impact. Every strategy deck has a Three Horizons slide. Almost no company uses the framework to actually govern resource allocation.
The framework’s value is not taxonomic — it is not just a way to categorize your innovation projects. Its value is that it forces an explicit conversation about three fundamentally different types of investment with different time horizons, risk profiles, return patterns, and management requirements.
Horizon 1 innovations improve existing products for existing customers. They are managed through normal product development processes, evaluated against established metrics, and funded from operating budgets. The risk is low, the return is predictable, and the time to market is typically 12-24 months. The problem with Horizon 1 dominance is not that H1 innovations are bad — they are necessary. The problem is that H1 thinking, applied to Horizon 2 and 3 opportunities, systematically kills them.
Horizon 2 innovations extend existing capabilities to adjacent markets or customer segments, or create new categories within existing markets. These take 2-5 years to develop meaningful revenue, require tolerance for iteration and some failure, and are best managed through separate governance and funding mechanisms. They should not go through the same Stage-Gate process as Horizon 1 — the same milestones and kill criteria that are appropriate for low-risk incremental development will systematically reject the more uncertain H2 opportunities.
Horizon 3 innovations are bets on future business models, technologies, or market positions that may take 5-10 years to materialize. Most companies cannot genuinely manage Horizon 3 internally — the time horizon is too long, the uncertainty too high, and the organizational patience too limited. For most industrial manufacturers, the practical Horizon 3 portfolio consists of strategic technology partnerships, minority investment in relevant startups, and participation in industry research consortia. The mistake is expecting Horizon 3 to behave like Horizon 1.
Info
Why ODI Changes the Portfolio Allocation Conversation
The most common failure mode in innovation portfolio management is that allocation decisions are made based on advocacy rather than evidence. Business units with strong internal voices get funded. Projects championed by respected engineering leaders survive stage-gate reviews that should have killed them. New growth opportunities proposed by less senior teams die because their advocates lack the organizational standing to defend them through budget cycles.
Outcome-Driven Innovation changes this dynamic by providing an evidence base that is independent of internal advocacy. When you have quantitative data showing that 28 specific customer outcomes are highly important and highly underserved by current solutions — including the specific market size implications of those opportunity clusters — the portfolio allocation debate changes character.
Instead of “our largest customer wants this feature,” you have “this outcome cluster represents underserved needs for 68% of the target segment, generating an addressable opportunity of approximately €X.” Instead of “our engineering team thinks this is technically interesting,” you have “this outcome cluster is important to customers but currently unaddressed by any competitive solution.”
This is what makes product strategy frameworks grounded in customer outcomes genuinely useful for portfolio management: they replace organizational power as the primary allocation driver with customer evidence.
In practice, the ODI-informed portfolio process works as follows:
- Run outcome mapping and quantification for each major product line annually (or biannually for stable markets).
- Generate opportunity scores for all measured outcomes — the standard ODI formula: importance + (importance − satisfaction).
- Cluster outcomes by opportunity score into three categories: overserved (low priority), appropriately served (maintain), and underserved (high priority).
- Map the underserved opportunity clusters across the Three Horizons: which can be addressed through Horizon 1 improvements, which require Horizon 2 platform development, which point toward genuinely new categories?
- Use this map to inform portfolio allocation decisions, with explicit targets for each horizon.
This process does not eliminate judgment — strategic priorities, competitive timing, and resource constraints all matter. But it grounds the judgment in customer evidence rather than organizational politics.
The Core Business Is Not the Enemy of Innovation
There is a seductive narrative in innovation management circles that the core business is the primary obstacle to innovation. The “core” demands resources, captures management attention, resists organizational change, and reliably wins political battles against exploratory projects.
This narrative is partly true and partly a convenient excuse. The core business funds everything. Without healthy core economics, the innovation portfolio is theoretical. A company that starves its Horizon 1 optimization to fund exploratory innovation typically ends up with neither: a declining core and a Horizon 2/3 portfolio that lacks the sustained funding required to reach commercialization.
The right framing is not “core versus new” — it is “core optimized efficiently enough to fund the full portfolio.” This requires honest assessment of where core business investment creates genuine value versus where it is defending positions that are not economically or competitively worth defending.
At a construction equipment manufacturer, we found that approximately 35% of the engineering resources allocated to Horizon 1 improvements were going to product variants that addressed the needs of a customer segment representing less than 8% of revenue, with below-average margins and high customization complexity. Redirecting half of that investment to Horizon 2 platform development required making explicit the cost of the variant proliferation — a conversation that had been avoided because the relevant customers were vocal and the relevant sales team was protective.
The innovation portfolio conversation, at its best, forces these explicit trade-offs. You cannot fund everything. The question is whether the allocation reflects strategic intent or organizational inertia.
Governance: The Part Everyone Skips
Most discussions of innovation portfolio management focus on strategy and categorization — the horizon model, the portfolio mix, the criteria for different investment types. They spend less time on governance: who makes allocation decisions, with what authority, on what evidence, at what cadence.
This is a mistake. Innovation portfolios fail primarily for governance reasons, not strategy reasons. The strategy is typically right. The governance mechanisms are insufficient to implement it.
Effective innovation portfolio governance has these elements:
Separate funding pools by horizon. If Horizon 2 projects compete with Horizon 1 projects for the same engineering budget, Horizon 2 will lose most of the time. The short-term ROI of sustaining improvements is clearer, the risk is lower, and the internal customers are louder. Separate pools, funded at the strategic allocation levels, are the minimum structural requirement.
Separate review cadences. Horizon 1 investments should be reviewed quarterly against milestone and market performance. Horizon 2 investments should be reviewed semi-annually with tolerance for iteration. Horizon 3 should be reviewed annually with different success criteria — typically learning achieved, not revenue generated.
Separate success metrics. Applying revenue and margin expectations to Horizon 2 and 3 projects at early stages — as most companies do — creates systematic bias toward short-term thinking. Define what success looks like at each stage of a Horizon 2 project: market hypothesis tested, customer adoption achieved, unit economics understood. These are appropriate early-stage metrics. Quarterly P&L contribution is not.
An investment committee with appropriate composition. Horizon 1 allocation decisions can be made by product management and business units. Horizon 2 and 3 allocation decisions require C-level participation — both because the amounts are material and because the political dynamics that kill exploratory investments are above the pay grade of middle management to resolve. A CEO or COO who is not actively protecting the Horizon 2/3 budget from the core business’s quarterly demands is not managing an innovation portfolio. They are managing the illusion of one.
See our work on innovation culture in enterprise for how organizational culture intersects with portfolio governance — culture that does not tolerate failure cannot sustain the Horizon 2/3 investment that requires it.
I have reviewed innovation portfolios at more than a dozen DACH manufacturers. The document is usually well-designed. The actual allocation of engineering time, when you track it over a quarter, almost never matches what the document says. The portfolio strategy and the resource reality are different documents because the governance that would keep them aligned does not exist. That is the problem to fix first.
Measuring Portfolio Health
Innovation portfolio management requires a measurement system that differs from standard business performance metrics. Conventional metrics — revenue, margin, market share — are lagging indicators that tell you about the output of innovation decisions made 3-5 years ago. They tell you nothing about the health of your current portfolio or the likely output it will produce.
Portfolio health metrics for an innovation portfolio include:
Innovation investment ratio by horizon. The proportion of innovation resources (people and budget) allocated to H1/H2/H3. Track this quarterly. If it is drifting toward 90%+ H1, investigate the governance failure that is causing the drift.
Opportunity coverage rate. Of the top-quartile customer outcome opportunities identified through ODI research, what percentage are addressed by current or planned innovation projects? A high coverage rate means your portfolio is well-aligned with market opportunity. A low rate means your portfolio is driven by internal priorities rather than customer needs.
Time-to-market by horizon. How long do Horizon 1, Horizon 2, and Horizon 3 projects take from concept to market? Tracking this reveals process bottlenecks and governance failures. Horizon 2 projects that take as long as major Horizon 1 initiatives are being managed with the wrong process.
Kill rate and kill quality. What percentage of projects are killed before reaching market? And of the projects that are killed, at what stage are they killed? Early-stage kills are evidence of effective portfolio management — failing fast and cheap. Late-stage kills (after major investment) suggest the portfolio governance is failing to surface bad projects early. For more on specific measurement approaches, see our article on innovation metrics and measurement.
Revenue contribution by vintage. What percentage of current revenue comes from products launched in the last 3 years? 5 years? This is the output metric for a portfolio management system. For most industrial manufacturers, a healthy target is 25-30% of revenue from products launched in the last 5 years.
Practical Starting Points
For organizations that recognize their portfolio management is not working but are unsure where to start:
Start with transparency. Before changing any allocation, map the current state accurately. Track engineering time by project type for one quarter. Categorize each project by horizon. Calculate the actual allocation ratio. Most organizations are surprised — often shocked — by how concentrated their investment actually is.
Define your target allocation explicitly. Based on your competitive environment, growth ambitions, and core business health, define what the right H1/H2/H3 allocation should be for your organization. For most DACH industrial manufacturers facing moderate competitive pressure, a reasonable target is 70/20/10. Write it down. Make it public. Make it the standard against which actual allocation is evaluated.
Build the governance infrastructure. Create separate funding pools. Define separate review cadences. Establish which decisions require which level of organizational authority. This is organizational plumbing — unsexy but essential.
Ground the portfolio in customer evidence. Conduct outcome mapping for your highest-priority product areas. Use the opportunity data to challenge portfolio priorities that are not grounded in evidence of customer need. The projects that survive this challenge are the ones worth protecting.
Frequently Asked Questions
Innovation portfolio management is not a creative exercise. It is a governance discipline that requires explicit structures, transparent metrics, and leadership commitment strong enough to override the organizational gravity that pulls every resource toward the most immediate and certain returns.
The companies that manage this well are not special in their creativity or their risk appetite. They are disciplined in their governance and honest about their allocation. That discipline is achievable in any organization that is willing to make the current state visible and hold itself accountable to a better one.
Is Your Innovation Portfolio Aligned With Market Opportunity?
Book a complimentary discovery call to explore how these ideas apply to your organization.
